We cordially invite you to attend a symposium on July 27th that centers around CAR-T and Bispecifics. This event aims to engage with community oncologists and exchange ideas on the obstacles they encounter in their practice. We would be honored to have your valued participation…

If you or your student, resident, fellow need a quick refresher on how to manage #BCMA associated cytopenias, aka #ICAHT , please check out our new article below.. #mmsm Mary McGann Jessie Marini Hamza Hashmi #oncopharm
tandfonline.com/doi/full/10.10…

12 Reasons Doctors Don’t Work at the VA

whitecoatinvestor.com/12-reasons-doc…
#MedTwitter #MedEd #USMIRC USMIRC News

Oncologist Shortage: Can Fellowship Changes Help? Developing fellowship programs that increase trainee exposure to community oncology could help improve access to oncologists in rural areas, experts said. #Medtwitter #MedEd #USMIRC ⁦USMIRC News⁩ obroncology.com/article/oncolo…

Treg depletion supercharges ASCT power ashpublications.org/blood/article/… #mmsm #USMIRC USMIRC News #MedEd #medtwitter ASH

Daratumumab/Pom/Dex (DPd) in relapse #Myeloma ; the incidence of dose reduction/interruption was 76%, due to hematological toxicity in 73%! The most common reason for discontinuing treatment was disease progression in 61%

#MedTwitter #MedEd @OncAlert USMIRC News #USMIRC #mmsm …

Idecabtagene Vicleucel in Early Relapsed/Refractory Myeloma: Is There an Efficacy Benefit? | ASCO Daily News
url.us.m.mimecastprotect.com/s/UwVACM825xuq…
#ASCODailyNews ASCO USMIRC News #mmsm #myeloma #USMIRC Shebli Atrash Al-Ola A Abdallah MD (USMIRC)

ODAC voted on 4/12/2024 to use MRD as a surrogate endpoint for #myeloma Clinical trials
#mmsm #USMIRC USMIRC News U.S. FDA FDA Oncology

Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma
#mmsm #myeloma #MedEd #MedTwitter #USMIRC USMIRC News
haematologica.org/article/view/h…

🚨 CARVYKTI is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with RRMM Who Have Received at Least One Prior Line of Therapy
#mmsm #MedTwitter #myeloma #USMIRC USMIRC News JanssenUS
prnewswire.com/news-releases/…

Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with RRMM

pubmed.ncbi.nlm.nih.gov/38142943/
James Davis, PharmD, BCOP Danai Dima Nausheen Ahmed MD Hamza Hashmi Faiz Anwer MD Al-Ola A Abdallah MD (USMIRC) USMIRC News #USMIRC #MedTwitter #mmsm #myeloma #MedEd

Clinical efficacy of retreatment of daratumumab-based therapy (D2) in daratumumab-refractory multiple myeloma #mmsm #myeloma #MedTwitter #MedEd #USMIRC USMIRC News #hematology #Oncology

onlinelibrary.wiley.com/doi/abs/10.111…

Breaking News: Kate Middleton announces she’s been diagnosed with cancer and underwent abdominal surgery in London! Oncology team recommend preventative chemotherapy
#mmsm #Oncology #MedTwitter #USMIRC USMIRC News

ICE-T symposium ⏳ 127 days remaining #USMIRC USMIRC News #MedTwitter #MedEd #mmsm #myeloma KU Cancer Center KU Hospital News

CARTITUDE-4 Cilta-Cel vs. SOC (DPd or PVd) in patients with RRMM (lenalidomide refractory) showed better PFS and OS
nejm.org/doi/full/10.10…

#mmsm #MedEd #USMIRC USMIRC News #MedTwitter

Congratulations 🎉 to all Myeloma patients for 2 CAR-Ts that received a yes per ODAC to move upfront
#mmsm #myeloma #MedTwitter #MedEd #USMIRC USMIRC News

ODAC voted ✅ that Cilta-Cel for early relapse myeloma #mmsm #myeloma USMIRC News #USMIRC

I am interested in this study if this is applicable clinically, it will be a real game changer on many different levels:
Waking up exhausted BCMA-specific T cells in myeloma
#mmsm #MedEd #Myeloma #medtwitter #USMIRC USMIRC News
ashpublications.org/blood/article/…